These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 25132683)
1. Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment. Miyata K; Takagi S; Sato S; Morioka H; Shiba K; Minamisawa T; Takami M; Fujita N Cancer Med; 2014 Dec; 3(6):1595-604. PubMed ID: 25132683 [TBL] [Abstract][Full Text] [Related]
2. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Nakazawa Y; Takagi S; Sato S; Oh-hara T; Koike S; Takami M; Arai H; Fujita N Cancer Sci; 2011 Nov; 102(11):2051-7. PubMed ID: 21824222 [TBL] [Abstract][Full Text] [Related]
3. Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis. Takagi S; Oh-hara T; Sato S; Gong B; Takami M; Fujita N Int J Cancer; 2014 Jun; 134(11):2605-14. PubMed ID: 24222607 [TBL] [Abstract][Full Text] [Related]
4. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. Takagi S; Sato S; Oh-hara T; Takami M; Koike S; Mishima Y; Hatake K; Fujita N PLoS One; 2013; 8(8):e73609. PubMed ID: 23991201 [TBL] [Abstract][Full Text] [Related]
5. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Kunita A; Kashima TG; Morishita Y; Fukayama M; Kato Y; Tsuruo T; Fujita N Am J Pathol; 2007 Apr; 170(4):1337-47. PubMed ID: 17392172 [TBL] [Abstract][Full Text] [Related]
6. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Nakazawa Y; Sato S; Naito M; Kato Y; Mishima K; Arai H; Tsuruo T; Fujita N Blood; 2008 Sep; 112(5):1730-9. PubMed ID: 18541721 [TBL] [Abstract][Full Text] [Related]
7. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352 [TBL] [Abstract][Full Text] [Related]
8. The impact of Aggrus/podoplanin on platelet aggregation and tumour metastasis. Fujita N; Takagi S J Biochem; 2012 Nov; 152(5):407-13. PubMed ID: 22992842 [TBL] [Abstract][Full Text] [Related]
9. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030 [TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973 [TBL] [Abstract][Full Text] [Related]
11. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. Kato Y; Fujita N; Kunita A; Sato S; Kaneko M; Osawa M; Tsuruo T J Biol Chem; 2003 Dec; 278(51):51599-605. PubMed ID: 14522983 [TBL] [Abstract][Full Text] [Related]
12. Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells. Kaneko M; Kato Y; Kunita A; Fujita N; Tsuruo T; Osawa M J Biol Chem; 2004 Sep; 279(37):38838-43. PubMed ID: 15231832 [TBL] [Abstract][Full Text] [Related]
13. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis. Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681 [TBL] [Abstract][Full Text] [Related]
14. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532 [TBL] [Abstract][Full Text] [Related]
15. Platelet-activating factor podoplanin: from discovery to drug development. Takemoto A; Miyata K; Fujita N Cancer Metastasis Rev; 2017 Jun; 36(2):225-234. PubMed ID: 28674748 [TBL] [Abstract][Full Text] [Related]